These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 14513664)

  • 1. Benzodiazepine utilization patterns in Alzheimer's disease patients.
    Lagnaoui R; Moore N; Moride Y; Miremont-Salamé G; Bégaud B
    Pharmacoepidemiol Drug Saf; 2003 Sep; 12(6):511-5. PubMed ID: 14513664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease.
    Semla TP; Cohen D; Freels S; Paveza GJ; Ashford JW; Gorelick P; Luchins D; Eisdorfer C
    Pharmacotherapy; 1995; 15(4):495-501. PubMed ID: 7479203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
    Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
    Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD).
    Demyttenaere K; Bonnewyn A; Bruffaerts R; De Girolamo G; Gasquet I; Kovess V; Haro JM; Alonso J
    J Affect Disord; 2008 Sep; 110(1-2):84-93. PubMed ID: 18329721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
    J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insomnia, depression and anxiety disorders and their association with benzodiazepine drug use among the community-dwelling elderly: implications for mental health nursing.
    Voyer P; Landreville P; Moisan J; Tousignant M; Préville M
    Int J Psychiatr Nurs Res; 2005 Jan; 10(2):1093-116. PubMed ID: 15715320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
    Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
    J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of the concomitant use of clozapine and benzodiazepines: a retrospective, cross-sectional chart review.
    Bitter R; Demler TL; Opler L
    J Psychiatr Pract; 2008 Sep; 14(5):265-70. PubMed ID: 18832957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer).
    Tifratene K; Duff FL; Pradier C; Quetel J; Lafay P; Schück S; Benzenine E; Quantin C; Robert P
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):1005-12. PubMed ID: 22718684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].
    Gil-Néciga E; Gobartt AL;
    Rev Neurol; 2008 Apr 16-30; 46(8):461-4. PubMed ID: 18428102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessment.
    Wilcock GK; Ashworth DL; Langfield JA; Smith PM
    Br J Gen Pract; 1994 Jan; 44(378):30-3. PubMed ID: 8312036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
    Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
    Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Short- and long-term results of a systematic benzodiazepine discontinuation programme for psychiatric patients].
    Kan CC; Mickers FC; Barnhoorn D
    Tijdschr Psychiatr; 2006; 48(9):683-93. PubMed ID: 17007474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment.
    Vellas B; Lauque S; Gillette-Guyonnet S; Andrieu S; Cortes F; Nourhashémi F; Cantet C; Ousset PJ; Grandjean H;
    J Nutr Health Aging; 2005; 9(2):75-80. PubMed ID: 15791349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort.
    Gillette-Guyonnet S; Cortes F; Cantet C; Vellas B;
    J Nutr Health Aging; 2005; 9(2):69-73. PubMed ID: 15791348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.